ClinicalTrials.gg
CompletedNCT02228239DRiVESaFeUpdated Dec 30, 2014

Study to Assess the Effects of Esketamine on Safety of On-road Driving in Healthy Participants

A Phase 1 interventional study of Esketamine and Mirtazapine in Healthy, sponsored by Janssen Research & Development, LLC. Completed at 1 site in Netherlands. Open to participants aged 21 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-12-30.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
21 Years to 60 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the effect of esketamine compared to placebo on driving performance as assessed by the mean difference of standard deviation of lateral position (SDLP) from an on-road driving test in healthy participants.

Read the detailed description

This is a Phase 1, randomized (study medication assigned to participants by chance), double-blind (neither Investigator nor participant knows which treatment the participant receives), placebo-controlled (placebo is an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial), single-center, single-dose and 3-way crossover (the same medications provided to all participants but in different sequence) study of esketamine in healthy participants. Participants will be randomly assigned to 1 of 6 treatment sequences. The study will consist of 3 parts: Screening Phase (between 21 days and 1 day prior to the first dose administration), a 3-way crossover double-blind, single dose treatment Phase (45 days) and follow-up Phase (7 to 10 days after last dose administration). The maximum study duration for each participant will not exceed 7 weeks. Participants will receive either Treatment A (esketamine 84 milligram (mg) intranasal and 1 placebo capsule), Treatment B (placebo intranasal and 1 mirtazapine 30 mg capsule) or Treatment C (placebo intranasal and placebo capsule) in each treatment period. Driving performance will be assessed primarily by the mean difference of SDLP from an on road driving test. Participants' safety will be monitored throughout the study.

02

Conditions studied

  • Healthy

Keywords

  • Healthy
  • Esketamine
  • Mirtazapine
  • Psychomotor.
03

In context

Lead sponsor

Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.

Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) (weight [kg]/height\^2[m\^2]) between 18 and 30 kg/m\^2 (inclusive), and body weight not less than 45 kg
  • Blood pressure (after the participants is supine for 5 minutes) between 90 and 140 millimeter of mercury (mmHg) systolic, inclusive, and no higher than 90 mmHg diastolic at Screening and pre-dose on Day 1 of Period 1
  • A woman of must have a negative urine pregnancy test at Screening and pre-dose on Day 1 of Period 1
  • A 12-lead (ECG) consistent with normal cardiac conduction and function at Screening and pre-dose on Day 1 of Period 1, including: sinus rhythm, heart rate between 45 and 90 beats per minute (bpm), less than or equal to 450 milliseconds (ms), QRS interval of less than 120 ms, PR interval less than 200 ms and morphology consistent with healthy cardiac conduction and function 1st degree AV block is exclusionary
  • Participant has a valid driving license for more than 3 years, has driven at least 5000 kilometer (km) in the past year and is driving a car regularly

Exclusion criteria

Exclusion Criteria:

  • Participant has liver or renal insufficiency; cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic (including cataplexy and cognitive impairment), hematologic, rheumatologic, psychiatric, or metabolic disturbances. A significant primary sleep disorder is exclusionary
  • Clinically significant abnormal values for hematology, clinical chemistry, or urinalysis at Screening, as deemed appropriate by the Investigator
  • Clinically significant abnormal physical examination, vital signs, or 12-lead (ECG) at Screening or on Day 1 of Period 1, as deemed appropriate by the Investigator
  • Anatomical or medical conditions that may impede delivery or absorption of study medication (for example, undergone facial reconstruction, rhinoplasty, significant structural or functional abnormalities of the nose or upper airway; obstructions or mucosal lesions of the nostrils or nasal passages; undergone sinus surgery in the previous 2 years; or signs and symptoms of rhinitis predose on Day 1 of Period 1)
  • Has an abnormal or deviated nasal septum with any one or more of the following symptoms: blockage of one or both nostrils, nasal congestion (especially 1-sided), frequent nosebleeds, frequent sinus infections, and at times has facial pain, headaches, and postnasal drip
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Sequence 1 (ABC)

    Participants will receive Treatment A (esketamine 84 milligram (mg) intranasally and 1 placebo capsule) in Period 1, Treatment B (placebo intranasally and 1 mirtazapine 30 mg capsule) in Period 2 and Treatment C (placebo intranasally and placebo capsule) in Period 3 with a washout interval of at least 6 days between treatment periods.

    Drug: Esketamine · Drug: Mirtazapine · Drug: Placebo (Matched to Esketamine) · Drug: Placebo (Matched to Mirtazapine)

  • Experimental
    Sequence 2 (BCA)

    Participants will receive Treatment B (placebo intranasally and 1 mirtazapine 30 mg capsule) in Period 1, Treatment C (placebo intranasally and placebo capsule) in Period 2 and Treatment A (esketamine 84 mg intranasally and 1 placebo capsule) in Period 3 with a washout interval of at least 6 days between treatment periods.

    Drug: Esketamine · Drug: Mirtazapine · Drug: Placebo (Matched to Esketamine) · Drug: Placebo (Matched to Mirtazapine)

  • Experimental
    Sequence 3 (CAB)

    Participants will receive Treatment C (placebo intranasally and placebo capsule) in Period 1, Treatment A (esketamine 84 mg intranasally and 1 placebo capsule) in Period 2 and Treatment B (placebo intranasally and 1 mirtazapine 30 mg capsule) in Period 3 with a washout interval of at least 6 days between treatment periods.

    Drug: Esketamine · Drug: Mirtazapine · Drug: Placebo (Matched to Esketamine) · Drug: Placebo (Matched to Mirtazapine)

  • Experimental
    Sequence 4 (CBA)

    Participants will receive Treatment C (placebo intranasally and placebo capsule) in Period 1, Treatment B (placebo intranasally and 1 mirtazapine 30 mg capsule) in Period 2 and Treatment A (esketamine 84 mg intranasally and 1 placebo capsule) in Period 3 with a washout interval of at least 6 days between treatment periods.

    Drug: Esketamine · Drug: Mirtazapine · Drug: Placebo (Matched to Esketamine) · Drug: Placebo (Matched to Mirtazapine)

  • Experimental
    Sequence 5 (ACB)

    Participants will receive Treatment A (esketamine 84 mg intranasally and 1 placebo capsule) in Period 1, Treatment C (placebo intranasally and placebo capsule) in Period 2 and Treatment B (placebo intranasally and 1 mirtazapine 30 mg capsule) in Period 3 with a washout interval of at least 6 days between treatment periods.

    Drug: Esketamine · Drug: Mirtazapine · Drug: Placebo (Matched to Esketamine) · Drug: Placebo (Matched to Mirtazapine)

  • Experimental
    Sequence 6 (BAC)

    Participants will receive Treatment B (placebo intranasally and 1 mirtazapine 30 mg capsule) in Period 1, Treatment A (esketamine 84 mg intranasally and 1 placebo capsule) in Period 2 and Treatment C (placebo intranasally and placebo capsule) in Period 3 with a washout interval of at least 6 days between treatment periods.

    Drug: Esketamine · Drug: Mirtazapine · Drug: Placebo (Matched to Esketamine) · Drug: Placebo (Matched to Mirtazapine)

Interventions

  • Esketamine 84 milligram (mg) \[3\*1 of spray in each nostril\] will be administered intranasally on Day 1 in one of the treatment periods.

    Also known as: JNJ-54135419

  • Mirtazapine 30 mg capsule will be administered orally on Day 1 in one of the treatment periods.

  • DrugPlacebo (Matched to Esketamine)

    Placebo \[3\*1 in each nostril\] will be administered intranasally on Day 1 in one of the treatment periods.

  • DrugPlacebo (Matched to Mirtazapine)

    Placebo capsule will be administered orally on Day 1 in one of the treatment periods.

06

What researchers measure

Primary outcomes

  1. Standard Deviation of Lateral Position (SDLP) Assessed From an On-road Driving Test

    The SDLP will be measured from a validated on-road driving test in a 100 kilometer (km) highway-driving lane.

    Time frame: 4 to 14 hours post-dose

Secondary outcomes

  1. Standard Deviation of Speed (SDS) Assessed From an On-road Driving Test

    The SDS will be measured from a validated on-road driving test in a 100 km highway-driving lane.

    Time frame: 4 to 14 hours post-dose

  2. Mean Speed (MS) Assessed From an On-road Driving Test

    The MS will be measured from a validated on-road driving test in a 100 km highway-driving lane.

    Time frame: 4 to 14 hours post-dose

  3. Mean Lateral Position (MLP) Assessed From an On-road Driving Test

    The MLP will be measured from a validated on-road driving test in a 100 km highway-driving lane.

    Time frame: 4 to 14 hours post-dose

  4. Subjective Driving Performance Score

    Participants will indicate the perceived quality of their driving performance on a visual analog scale, which ranges from 0 ('I drove exceptionally poorly') to 20 ('I drove exceptionally well').

    Time frame: After completion of driving test (4 to 14 hours post-dose)

  5. Karolinska Sleepiness Scale (KSS) Score

    The KSS is a participant-reported assessment used to rate sleepiness on a scale of 1 to 9, ranging from 1 (extremely alert) to 9 (very sleepy, great effort to keep awake, fighting sleep).

    Time frame: Pre-dose, 1, 2 hours and after completion of driving test (4 to 14 hours post-dose)

  6. Columbia Suicide Severity Rating Scale (C-SSRS) Score

    The C-SSRS is a low-burden measure of the spectrum of suicidal ideation and behavior developed to assess severity and track suicidal events providing a summary of both suicidal ideation and behavior to identify the level and type of suicidality present.

    Time frame: Up to 7 to 10 days after last dose administration

  7. Brief Psychiatric Rating Scale (BPRS) Symptom Sub-Scale Score

    The BPRS is an 18-item rating scale which is used to assess a range of psychotic and affective symptoms rated from both observation of the participant and the participant's own report. Only the 4-item positive symptom subscale (consisting of: suspiciousness/persecution, hallucinations, unusual thought content, and conceptual disorganization) will be used and each question is rated on a 7-point scale ranging from 0 (not present) to 6 (extremely severe).

    Time frame: Pre-dose, 1 and 2 hours post-dose

  8. Clinician Administered Dissociative States Scale (CADSS) Score

    The CADSS is an instrument for the measurement of present-state dissociative symptoms. The CADSS comprises 23 subjective items, divided into 3 components: Depersonalization, Derealization and Amnesia. Participant's responses are coded on a 5-point scale (0 = "Not at all" through to 4 = "Extremely").

    Time frame: Pre-dose, 1 and 2 hours post-dose

  9. Maximum plasma concentration (Cmax)

    The Cmax is the maximum observed plasma concentration of esketamine or noresketamine.

    Time frame: Pre-dose, 0.5, 1, 3 and 4 hours post-dose

07

Study locations

1 site
  • Leiden, Netherlands
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2014, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2014
First posted
Aug 28, 2014
Start
Sep 2014
Primary completionActual
Dec 2014
CompletionActual
Dec 2014
Last update
Dec 30, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02228239
Responsible party
Sponsor
First posted
Aug 28, 2014
Start date
Sep 2014
Primary completion
Dec 2014
Completion
Dec 2014
Last update
Dec 30, 2014

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esketamine

Start the discussion